You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

untreated metastatic squamous neck cancer with occult primary

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell

Active, not recruiting
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +29 more
  • Cytology specimen
  • Laboratory biomarker analysis
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
Aug 31, 2021

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Head Neck Cancer Metastatic Trial in Baltimore (Nivolumab 480mg and

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Nivolumab 480mg and surgical resection
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Feb 25, 2022

Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)

Not yet recruiting
  • Metastatic Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Portland, Oregon
    Providence Portland Medical Center
Jun 19, 2023

Head and Neck Squamous Cell Carcinoma Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 17, 2023

Prognostic Immune Biomarkers in HNSCC

Completed
  • Head and Neck Cancer
  • Squamous Cell Carcinoma
  • Tumour immunoprofile evaluation
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Jul 3, 2023

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Panitumumab
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Feb 16, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Cancer
  • (no location specified)
Jun 9, 2023

Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma Trial in Copenhagen, Århus

Recruiting
  • Cancer of Unknown Primary Site
  • +2 more
  • Transoral Ultrasound
  • Copenhagen, Denmark
  • +1 more
May 2, 2023

HLA-DR in Cell Cultures Isolated From Primary Squamous Cell

Active, not recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Cancer
  • cell culture
  • Roma, Lazio, Italy
    Fondazione Policlinico Universitario Gemelli, Irccs
Sep 11, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Recurrent Head Neck Cancer, Head Neck Cancer, Head and Neck Tumors Trial in Cincinnati (Durvalumab, Cetuximab)

Active, not recruiting
  • Recurrent Head and Neck Cancer
  • +3 more
  • Cincinnati, Ohio
    UC Health
Oct 3, 2022

Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous

Active, not recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • +3 more
  • 200 mg Pembrolizumab
  • +2 more
  • Miami, Florida
  • +6 more
Jan 9, 2023

Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),

Active, not recruiting
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Ibrutinib 560mg PO daily (Imbruvica)
  • +2 more
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 11, 2023

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)

Completed
Has Results
  • Head and Neck Squamous Cell Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Recurrent Head and Neck Squamous Cell Carcinoma Trial in Atlanta, Cleveland, Milwaukee (IMRT, Nivolumab)

Active, not recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • IMRT
  • Nivolumab
  • Atlanta, Georgia
  • +3 more
Jan 10, 2023

Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma Trial in China (TQB2618 injection,

Not yet recruiting
  • Recurrent Squamous Cell Carcinoma of the Head and Neck
  • Metastatic Squamous Cell Carcinoma
  • TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
  • Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
  • Lanzhou, Gansu, China
  • +11 more
Mar 23, 2023

Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity

Active, not recruiting
Has Results
  • Squamous Cell Carcinoma of the Oropharynx
  • +7 more
  • Tampa, Florida
  • +2 more
Dec 30, 2022

Head Neck Cancer Trial in Charleston (Pembrolizumab, Clopidogrel, acetylsalicylic acid)

Recruiting
  • Head and Neck Cancer
  • Charleston, South Carolina
    Medical University of South Carolina
Dec 22, 2022

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin Trial in Australia, United States (TH-4000)

Terminated
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • TH-4000 (Tarloxotinib)
  • Los Angeles, California
  • +9 more
Jan 9, 2023

Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck Trial

Not yet recruiting
  • Head and Neck Cancer
  • +4 more
  • Ozuriftamab Vedotin
  • PD-1 inhibitor
  • (no location specified)
Jul 28, 2022

Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx

Active, not recruiting
Has Results
  • Head and Neck Squamous Cell Carcinoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2022

Head Neck Cancer, Head and Neck Squamous Cell Carcinoma Trial (ALE.C04, Pembrolizumab)

Not yet recruiting
  • Head and Neck Cancer
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Sep 19, 2023